Benefit from routine anticoagulation therapy to reduce risk of ischemic stroke may be unlikely in patients with atrial fibrillation and a CHA2DS2-VASc score of 1, according to a study published in the Jan. 27 issue of the Journal of the American College of Cardiology.
For patients with paroxysmal atrial fibrillation who undergo atrial fibrillation ablation, a high ablation effectiveness quotient correlates with freedom from atrial tachyarrhythmia, according to a study published online Jan. 15 in the Journal of Cardiovascular Electrophysiology.
An analysis of medical records from 5,311 people indicates that even mildly elevated blood pressure may indicate a dramatically elevated risk of developing atrial fibrillation (AF).
Many studies have shown that patients with hypertension — defined as blood pressure above 140/90 mm Hg — are more likely to develop AF than patients with healthy blood pressure, but the new paper may be the first to document a significant association between AF and blood pressure between 120/80 mm Hg and 139/89 mm Hg.
The US Food and Drug Administration (FDA) approved Savaysa (edoxaban tablets), an anti-clotting drug, to treat patients afflicted with atrial fibrillation prone to stroke and severe blood clots, not caused by a heart valve problem.
A new study indicates that left atria enlargement after catheter ablation for paroxysmal atrial fibrillation (AF) increases the risk that the condition will recur after a second ablation.
A new analysis of nearly 800 patient records has found an association between the oral anticoagulants used to treat atrial fibrillation and cerebral microbleeds.